San Francisco, CA, October 19, 2022 – Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories:
- Tempo-iBMEC™ – Human iPSC-derived Brain Microvascular Endothelial Cells
- Tempo-iPeri™ – Human iPSC-derived Pericytes
Tempo-iBMEC™ and Tempo-iPeri™ are critical for establishing patient-relevant blood-brain-barrier models to improve the drug development process for a growing number of therapeutic modalities (e.g., small molecules, biologics, gene therapies, CAR-T/NK therapies, siRNA/mRNA therapies). Combining these new products with existing products from Tempo, the human blood-brain-barrier is shown to be an orchestrated, dynamic and regulated barrier.
These new products add to the already-existing Tempo Bioscience product lines and expand the TempoStemBank™ Disease Model offerings. Currently, more than twenty-two iPSC-derivative cell types are offered to create patient-relevant disease models. TempoATP™, TempoMito™, TempoCal™, TempoO2™ and TempoVol™ biosensors are live-cell reporters of cellular, mitochondrial, and cytotoxicity functions.
Tempo Bioscience is the sole manufacturer of human iPSC-derived cell types that are engineered using non-viral, nucleic-acids-free, serum-free, and feeder-free technologies. Tempo is committed to advancing technologies that focus on disease modeling and drug safety evaluations using advanced human iPSC-derived cell models in 2D, as well as in 3D as spheroids or organoids. Tempo’s patient-relevant cell models aim to improve drug efficacy evaluations and safety assessments during drug development.
About Tempo Bioscience, Inc.
Tempo is a technology development focused biotechnology company based in San Francisco, California. Tempo develops and manufactures human iPSC-based biosensor enabling technologies for the biotech, pharmaceutical, and consumer product industries.
To learn more about this rapidly expanding market, view the “Global Induced Pluripotent Stem Cell (iPSC) Industry Report, 2022.”
